A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and...
Patient Power Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer Multidisciplinary Team at Karmanos, discusses the four stages of invasive ductal carcinoma (IDC), the IDC grading system, and the symptoms of this type of breast cancer. Read the article here .
Researchers at the Barbara Ann Karmanos Cancer Institute have published a review article in the American Journal of Clinical Oncology on the standard of care for hormone receptor-positive, early-stage breast cancer. The study, “A Review of Endocrine Therapy in Early-Stage Breast Cancer: The Journey from Crudeness to Precision,” discusses how treatment models for hormone-positive breast cancer need to be more personalized. “This article summarizes the milestone trials of a new era in treating hormone-pos...